vs
Amphastar Pharmaceuticals, Inc.（AMPH）与null（SWIM）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是null的1.8倍（$183.1M vs $100.0M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -7.0%，领先20.4%），null同比增速更快（14.5% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $14.1M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs -4.9%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
该企业是一家源自美国的跨国律师事务所，1934年创立于加利福尼亚州洛杉矶，在诉讼业务、公司法务以及监管合规法律领域拥有深厚的行业积累与知名度，是全球颇具影响力的综合性律所之一。
AMPH vs SWIM — 直观对比
营收规模更大
AMPH
是对方的1.8倍
$100.0M
营收增速更快
SWIM
高出16.4%
-1.8%
净利率更高
AMPH
高出20.4%
-7.0%
自由现金流更多
AMPH
多$10.5M
$14.1M
两年增速更快
AMPH
近两年复合增速
-4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $100.0M |
| 净利润 | $24.4M | $-7.0M |
| 毛利率 | 46.8% | 28.0% |
| 营业利润率 | 19.4% | -10.7% |
| 净利率 | 13.3% | -7.0% |
| 营收同比 | -1.8% | 14.5% |
| 净利润同比 | -35.7% | 76.0% |
| 每股收益（稀释后） | $0.51 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHSWIM
| Q4 25 | $183.1M | $100.0M | ||
| Q3 25 | $191.8M | $161.9M | ||
| Q2 25 | $174.4M | $172.6M | ||
| Q1 25 | $170.5M | $111.4M | ||
| Q4 24 | $186.5M | $87.3M | ||
| Q3 24 | $191.2M | $150.5M | ||
| Q2 24 | $182.4M | $160.1M | ||
| Q1 24 | $171.8M | $110.6M |
净利润AMPHSWIM
| Q4 25 | $24.4M | $-7.0M | ||
| Q3 25 | $17.4M | $8.1M | ||
| Q2 25 | $31.0M | $16.0M | ||
| Q1 25 | $25.3M | $-6.0M | ||
| Q4 24 | $38.0M | $-29.2M | ||
| Q3 24 | $40.4M | $5.9M | ||
| Q2 24 | $37.9M | $13.3M | ||
| Q1 24 | $43.2M | $-7.9M |
毛利率AMPHSWIM
| Q4 25 | 46.8% | 28.0% | ||
| Q3 25 | 51.4% | 35.4% | ||
| Q2 25 | 49.6% | 37.1% | ||
| Q1 25 | 50.0% | 29.5% | ||
| Q4 24 | 46.5% | 24.6% | ||
| Q3 24 | 53.3% | 32.4% | ||
| Q2 24 | 52.2% | 33.1% | ||
| Q1 24 | 52.4% | 27.7% |
营业利润率AMPHSWIM
| Q4 25 | 19.4% | -10.7% | ||
| Q3 25 | 13.2% | 13.3% | ||
| Q2 25 | 24.2% | 14.3% | ||
| Q1 25 | 21.9% | -4.4% | ||
| Q4 24 | 24.2% | -14.9% | ||
| Q3 24 | 29.8% | 8.9% | ||
| Q2 24 | 30.3% | 12.5% | ||
| Q1 24 | 27.9% | -1.9% |
净利率AMPHSWIM
| Q4 25 | 13.3% | -7.0% | ||
| Q3 25 | 9.0% | 5.0% | ||
| Q2 25 | 17.8% | 9.3% | ||
| Q1 25 | 14.8% | -5.4% | ||
| Q4 24 | 20.4% | -33.4% | ||
| Q3 24 | 21.1% | 3.9% | ||
| Q2 24 | 20.8% | 8.3% | ||
| Q1 24 | 25.1% | -7.1% |
每股收益（稀释后）AMPHSWIM
| Q4 25 | $0.51 | $-0.06 | ||
| Q3 25 | $0.37 | $0.07 | ||
| Q2 25 | $0.64 | $0.13 | ||
| Q1 25 | $0.51 | $-0.05 | ||
| Q4 24 | $0.74 | $-0.24 | ||
| Q3 24 | $0.78 | $0.05 | ||
| Q2 24 | $0.73 | $0.11 | ||
| Q1 24 | $0.81 | $-0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | — |
| 总债务越低越好 | $608.7M | $279.8M |
| 股东权益账面价值 | $788.8M | $405.9M |
| 总资产 | $1.6B | $823.2M |
| 负债/权益比越低杠杆越低 | 0.77× | 0.69× |
8季度趋势，按日历期对齐
现金及短期投资AMPHSWIM
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
总债务AMPHSWIM
| Q4 25 | $608.7M | $279.8M | ||
| Q3 25 | $608.6M | $281.1M | ||
| Q2 25 | $607.7M | $281.5M | ||
| Q1 25 | $603.9M | $306.9M | ||
| Q4 24 | $601.6M | $281.5M | ||
| Q3 24 | $596.4M | $282.8M | ||
| Q2 24 | $586.9M | $282.4M | ||
| Q1 24 | $594.0M | $282.8M |
股东权益AMPHSWIM
| Q4 25 | $788.8M | $405.9M | ||
| Q3 25 | $776.7M | $408.4M | ||
| Q2 25 | $757.5M | $398.4M | ||
| Q1 25 | $751.3M | $381.1M | ||
| Q4 24 | $732.3M | $387.2M | ||
| Q3 24 | $727.7M | $416.6M | ||
| Q2 24 | $713.3M | $408.1M | ||
| Q1 24 | $672.4M | $391.8M |
总资产AMPHSWIM
| Q4 25 | $1.6B | $823.2M | ||
| Q3 25 | $1.7B | $844.4M | ||
| Q2 25 | $1.6B | $822.1M | ||
| Q1 25 | $1.6B | $824.6M | ||
| Q4 24 | $1.6B | $794.2M | ||
| Q3 24 | $1.5B | $853.4M | ||
| Q2 24 | $1.5B | $830.0M | ||
| Q1 24 | $1.6B | $808.6M |
负债/权益比AMPHSWIM
| Q4 25 | 0.77× | 0.69× | ||
| Q3 25 | 0.78× | 0.69× | ||
| Q2 25 | 0.80× | 0.71× | ||
| Q1 25 | 0.80× | 0.81× | ||
| Q4 24 | 0.82× | 0.73× | ||
| Q3 24 | 0.82× | 0.68× | ||
| Q2 24 | 0.82× | 0.69× | ||
| Q1 24 | 0.88× | 0.72× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $23.3M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $14.1M |
| 自由现金流率自由现金流/营收 | 13.4% | 14.1% |
| 资本支出强度资本支出/营收 | 4.5% | 9.2% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $38.0M |
8季度趋势，按日历期对齐
经营现金流AMPHSWIM
| Q4 25 | $32.9M | $23.3M | ||
| Q3 25 | $52.6M | $51.0M | ||
| Q2 25 | $35.6M | $36.0M | ||
| Q1 25 | $35.1M | $-46.9M | ||
| Q4 24 | $29.0M | $6.2M | ||
| Q3 24 | $60.0M | $37.2M | ||
| Q2 24 | $69.1M | $52.4M | ||
| Q1 24 | $55.3M | $-34.5M |
自由现金流AMPHSWIM
| Q4 25 | $24.6M | $14.1M | ||
| Q3 25 | $47.2M | $45.2M | ||
| Q2 25 | $25.0M | $29.1M | ||
| Q1 25 | $24.4M | $-50.3M | ||
| Q4 24 | $16.6M | $-98.0K | ||
| Q3 24 | $46.2M | $33.2M | ||
| Q2 24 | $63.1M | $47.9M | ||
| Q1 24 | $46.5M | $-39.9M |
自由现金流率AMPHSWIM
| Q4 25 | 13.4% | 14.1% | ||
| Q3 25 | 24.6% | 27.9% | ||
| Q2 25 | 14.3% | 16.8% | ||
| Q1 25 | 14.3% | -45.2% | ||
| Q4 24 | 8.9% | -0.1% | ||
| Q3 24 | 24.1% | 22.1% | ||
| Q2 24 | 34.6% | 29.9% | ||
| Q1 24 | 27.1% | -36.0% |
资本支出强度AMPHSWIM
| Q4 25 | 4.5% | 9.2% | ||
| Q3 25 | 2.8% | 3.6% | ||
| Q2 25 | 6.1% | 4.0% | ||
| Q1 25 | 6.3% | 3.1% | ||
| Q4 24 | 6.7% | 7.2% | ||
| Q3 24 | 7.2% | 2.7% | ||
| Q2 24 | 3.3% | 2.8% | ||
| Q1 24 | 5.1% | 4.8% |
现金转化率AMPHSWIM
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 6.29× | ||
| Q2 25 | 1.15× | 2.25× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 6.32× | ||
| Q2 24 | 1.82× | 3.95× | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SWIM
| In Ground Swimming Pools | $50.2M | 50% |
| Covers | $37.0M | 37% |
| Liners | $12.7M | 13% |
